Literature DB >> 19756503

Evaluation of "Loss" and "End stage renal disease" after acute kidney injury defined by the Risk, Injury, Failure, Loss and ESRD classification in critically ill patients.

Rodrigo Cartin-Ceba1, Eric N Haugen, Remzi Iscimen, Cesar Trillo-Alvarez, Luis Juncos, Ognjen Gajic.   

Abstract

PURPOSE: The Risk, Injury, Failure, Loss and ESRD (RIFLE) classification has been widely accepted for the definition of acute kidney injury (AKI); however, no study has described in detail the last two stages of the classification: "Loss" and "ESRD". We aim to describe and evaluate the development of "Loss" and "ESRD" in a group of critically ill patients.
METHODS: We conducted a retrospective analysis of cases prospectively collected from the Acute Physiology and Chronic Health Assessment (APACHE III) database. Subjects were consecutive critically ill patients >18 years of age admitted to three ICUs of two tertiary care academic hospitals, from January 2003 through August 2006, excluding those who denied research authorization, chronic hemodialysis therapy, kidney transplant recipients, readmissions, and admissions for less than 12 h for low risk monitoring.
RESULTS: 11,644 patients were included in the study. The median age was 66 (interquartile range, 52-76), 90% were Caucasians and 54% of the patients were male. Half of the patients developed AKI, and most of the patients were in the Risk and Injury stages. From the patients that developed AKI, a total of 1,065 (19%) patients required renal replacement therapy (RRT), 415 (39%) underwent continuous renal replacement therapy (CRRT) and 650 (61%) underwent intermittent hemodialysis. A total of 281 patients on RRT did not survive hospital discharge, 97 patients progressed to "Loss", and 282 patients progressed to "ESRD". After multivariable adjustment, the progression to "ESRD" was associated with higher baseline creatinine, odds ratio (OR) 1.19 per every increase in creatinine of 0.1 mg/dl (95% CI, 1.11-1.29) P < 0.001; and less frequent use of CRRT, OR 0.18 (95% CI, 0.11-0.29) P < 0.001.
CONCLUSION: In this large retrospective study we found that almost 50% developed some form of AKI as defined by the RIFLE classification. Of these, 19% required RRT, and 4.9% progressed to "ESRD". "ESRD" was more likely in patients with elevated baseline creatinine and those treated with intermittent hemodialysis.

Entities:  

Mesh:

Year:  2009        PMID: 19756503     DOI: 10.1007/s00134-009-1635-9

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  46 in total

1.  Daily hemodialysis and the outcome of acute renal failure.

Authors:  Helmut Schiffl; Susanne M Lang; Rainald Fischer
Journal:  N Engl J Med       Date:  2002-01-31       Impact factor: 91.245

2.  Acute kidney injury in the intensive care unit according to RIFLE.

Authors:  Marlies Ostermann; René W S Chang
Journal:  Crit Care Med       Date:  2007-08       Impact factor: 7.598

3.  Comment on "RIFLE classification in patients with acute kidney injury in need of renal replacement therapy" by Maccariello et al.

Authors:  Rinaldo Bellomo; John A Kellum; Claudio Ronco
Journal:  Intensive Care Med       Date:  2007-07-20       Impact factor: 17.440

4.  Acute renal failure after cardiac surgery: evaluation of the RIFLE classification.

Authors:  Anne Kuitunen; Antti Vento; Raili Suojaranta-Ylinen; Ville Pettilä
Journal:  Ann Thorac Surg       Date:  2006-02       Impact factor: 4.330

Review 5.  Developing a consensus classification system for acute renal failure.

Authors:  John A Kellum; Nathan Levin; Catherine Bouman; Norbert Lameire
Journal:  Curr Opin Crit Care       Date:  2002-12       Impact factor: 3.687

6.  The outcome of acute renal failure in the intensive care unit according to RIFLE: model application, sensitivity, and predictability.

Authors:  Nihal Y Abosaif; Yasser A Tolba; Mike Heap; Jean Russell; A Meguid El Nahas
Journal:  Am J Kidney Dis       Date:  2005-12       Impact factor: 8.860

7.  Renal recovery after severe acute renal failure.

Authors:  S M Bagshaw; G Mortis; T Godinez-Luna; C J Doig; K B Laupland
Journal:  Int J Artif Organs       Date:  2006-11       Impact factor: 1.595

8.  Continuous renal replacement therapy improves renal recovery from acute renal failure.

Authors:  Michael J Jacka; Xenia Ivancinova; R T Noel Gibney
Journal:  Can J Anaesth       Date:  2005-03       Impact factor: 5.063

9.  Risk factors influencing survival in ICU acute renal failure.

Authors:  F Cosentino; C Chaff; M Piedmonte
Journal:  Nephrol Dial Transplant       Date:  1994       Impact factor: 5.992

10.  RIFLE criteria for acute kidney injury in aortic arch surgery.

Authors:  George J Arnaoutakis; Azra Bihorac; Tomas D Martin; Philip J Hess; Charles T Klodell; A Ahsan Ejaz; Cyndi Garvan; Curtis G Tribble; Thomas M Beaver
Journal:  J Thorac Cardiovasc Surg       Date:  2007-10-29       Impact factor: 5.209

View more
  15 in total

Review 1.  Renal angina: an emerging paradigm to identify children at risk for acute kidney injury.

Authors:  Rajit K Basu; Lakhmir S Chawla; Derek S Wheeler; Stuart L Goldstein
Journal:  Pediatr Nephrol       Date:  2011-10-20       Impact factor: 3.714

2.  Approaches to the Management of Acute Kidney Injury in Children.

Authors:  Rajit K Basu; Derek S Wheeler
Journal:  Recent Pat Biomark       Date:  2011

Review 3.  Choice of renal replacement therapy modality and dialysis dependence after acute kidney injury: a systematic review and meta-analysis.

Authors:  Antoine G Schneider; Rinaldo Bellomo; Sean M Bagshaw; Neil J Glassford; Serigne Lo; Min Jun; Alan Cass; Martin Gallagher
Journal:  Intensive Care Med       Date:  2013-02-27       Impact factor: 17.440

Review 4.  Acute kidney injury-epidemiology, outcomes and economics.

Authors:  Oleksa Rewa; Sean M Bagshaw
Journal:  Nat Rev Nephrol       Date:  2014-01-21       Impact factor: 28.314

5.  S-Nitrosoglutathione ameliorates acute renal dysfunction in a rat model of lipopolysaccharide-induced sepsis.

Authors:  Devadoss J Samuvel; Anandakumar Shunmugavel; Avtar K Singh; Inderjit Singh; Mushfiquddin Khan
Journal:  J Pharm Pharmacol       Date:  2016-08-03       Impact factor: 3.765

6.  Modality of RRT and Recovery of Kidney Function after AKI in Patients Surviving to Hospital Discharge.

Authors:  Kelly V Liang; Florentina E Sileanu; Gilles Clermont; Raghavan Murugan; Francis Pike; Paul M Palevsky; John A Kellum
Journal:  Clin J Am Soc Nephrol       Date:  2015-12-17       Impact factor: 8.237

7.  Assessment of tumor necrosis factor alpha polymorphism TNF-α-238 (rs 361525) as a risk factor for development of acute kidney injury in critically ill patients.

Authors:  Sameer H Fatani; Abeer Ahmed ALrefai; Hiba S Al-Amodi; Hala F Kamel; Kasem Al-Khatieb; Hamdy Bader
Journal:  Mol Biol Rep       Date:  2018-07-05       Impact factor: 2.316

8.  Improved survival in severe paraquat poisoning with repeated pulse therapy of cyclophosphamide and steroids.

Authors:  Ja-Liang Lin; Dan-Tzu Lin-Tan; Kuan-Hsing Chen; Wen-Hung Huang; Ching-Wei Hsu; Hsiang-Hao Hsu; Tzung-Hai Yen
Journal:  Intensive Care Med       Date:  2011-02-15       Impact factor: 17.440

Review 9.  Year in review in Intensive Care Medicine 2009: I. Pneumonia and infections, sepsis, outcome, acute renal failure and acid base, nutrition and glycaemic control.

Authors:  Massimo Antonelli; Elie Azoulay; Marc Bonten; Jean Chastre; Giuseppe Citerio; Giorgio Conti; Daniel De Backer; François Lemaire; Herwig Gerlach; Goran Hedenstierna; Michael Joannidis; Duncan Macrae; Jordi Mancebo; Salvatore M Maggiore; Alexandre Mebazaa; Jean-Charles Preiser; Jerôme Pugin; Jan Wernerman; Haibo Zhang
Journal:  Intensive Care Med       Date:  2010-01-08       Impact factor: 17.440

Review 10.  Aminoglycosides in septic shock: an overview, with specific consideration given to their nephrotoxic risk.

Authors:  Alexandre Boyer; Didier Gruson; Stéphane Bouchet; Benjamin Clouzeau; Bui Hoang-Nam; Frédéric Vargas; Hilbert Gilles; Mathieu Molimard; Anne-Marie Rogues; Nicholas Moore
Journal:  Drug Saf       Date:  2013-04       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.